Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7841-7850

  Lassman, Andrew B ^a   Rossi, Michael R ^b   Razier, Jeffrey R ^c   Abrey, Lauren E ^a   Lieberman, Frank S ^d   Grefe, Chelsea N ^a   Lamborn, Kathleen ^e   Pao, William ^a   Shih, Alan H ^a   Kuhn, John G ^f   Wilson, Richard ^g   Nowak, Norma J ^b   Cowell, John K ^b   DeAngelis, Lisa M ^a   Wen, Patrick ^h   Gilbert, Mark R ⁱ   Chang, Susan ^e   Yung, W A ⁱ   Prados, Michael ^e   Holland, Eric C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER RECURRENCE; CHROMOSOME 21; CHROMOSOME 22; CHROMOSOME 6; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; EXON; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG TUMOR; MEDICAL SOCIETY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CLINICAL TRIALS; CLUSTER ANALYSIS; DISEASE PROGRESSION; EXONS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; GLIOMA; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; NUCLEIC ACID HYBRIDIZATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 27744506881     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0421     Document Type: Article

References (39)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
2. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol 2003;13:52-61.
3. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 1987;84:6899-903.
4. Kleihues P. Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1999;1:44-51.
5. Schlegel J. Stumm G, Brandle K, et al. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 1994;22:201-7.
6. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990;87:4207-11.
7. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
8. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55:3140-8.
9. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7.
10. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669-72.
11. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs [abstract]. J Clin Oncol 2004;22:1502.
12. Lieberman FS, Cloughesy T, Malkin M, et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy [abstract 421]. J Clin Oncol 2003;22:105.
13. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
14. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
15. Pao W, Miller V, Zakowski M. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
16. Cowell JK, Wang YD, Head K, Conroy J, McQuaid D, Nowak NJ. Identification and characterisation of constitutional chromosome abnormalities using arrays of bacterial artificial chromosomes. Br J Cancer 2004;90:860-5.
17. Cheung VG, Nowak N, Jang W, et al. Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature 2001;409:953-8.
18. Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-4.
19. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20:1453-4.
20. Rossi MR, Gaile D, Laduca J, et al. Identification of consistent novel submegabase deletions in low-grade oligodendrogliomas using array-based comparative genomic hybridization. Genes Chromosomes Cancer 2005;44:85-96.
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
22. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
23. Habas R, Kato Y, He X. Wm/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. Cell 2001;107:843-54.
24. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer [abstract 24]. Proc Am Soc Clin Oncol 2003.
25. Vogelbaum MA, Peerboom G, Stevens G, Barnett G, Brewer C. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results [abstract]. J Clin Oncol 2004;22:1558.
26. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
27. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ("Iressa," ZD1839) monotherapy for pretreated advanced non-small cell lung cancer: IDEAL1 and 2 [abstract LB-170]. Proc Am Assoc Cancer Res 2003;44:1362.
28. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer [abstract 1235]. Proc Am Soc Clin Oncol 2001.
29. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
30. Uhm JH, Ballman KV, Giannini C, et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma [abstract]. J Clin Oncol 2004;22:1505.
31. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41.
32. Pao W, Zakowski M, Cordon-Cardo C, Ben-Porat L, Kris MG, Miller VA. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib [abstract 7025]. J Clin Oncol 2004;22:619.
33. Franklin WA, Chansky K, Gumerlock PH, et al. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126) [abstract 7019]. J Clin Oncol 2004;22.
34. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
35. Stallings-Mann M, Wharen R, Thomas CY. Resistance of glioblastoma cells to an EGFR kinase inhibitor is associated with maintenance of signaling by phosphatidylinositol-3-kinase (PI3K) and constitutive phosphorylation of the Gab1/Gab2 adapter proteins [abstract 72]. Proc Am Soc Clin Oncol 2002.
36. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003;9:4340-6.
37. Pao W, Miller VA, Kris MG. "Targeting" the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol 2004;14:33-40.
38. Rich JN, Rasheed BK, Van H. EGFR mutations and sensitivity to gefitinib, comments. N Engl J Med 2004;351:1260.
39. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004;351:2883.